Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial
Por:
Leal, L, González, MDB, Castán, C, Meira, F, Dueñas, G, Pich, J, Hernández-Meneses, M, Rico, V, García-Pouton, N, Agüero, D, de Lazzari, E, Tomé, A, Herrera, S, Muñóz, J, Almuedo, A, Prieto-González, S, Castro, P, Marcos, MA, Tuset, M, Paredes, R, Carbonell, C, Dalmau, D, Martínez, JA, Soriano, A and García, F
Publicada:
5 feb 2026
Resumen:
In 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission (2.7; 95% CI, 1.11-6.62), lower risk of requiring mechanical ventilation (0.43; 95% CI, 0.20-0.93) and shorter hospitalization duration (p = 0.008). Mortality was similar between arms (p = 0.675). Twenty-eight patients receiving siltuximab required rescue therapy while only 5 receiving corticosteroids (p < 0.001). Furthermore, patients receiving corticosteroids had a 53% lower risk of confirmed bacterial or fungal invasive infections (RR 0.47; 95% CI, 0.23-0.95; p = 0.0096). Our results show that initial treatment with corticosteroids was more effective than siltuximab in preventing disease progression, reducing intensive care unit admission, mechanical ventilation, with shorter hospital stays, and fewer infection in COVID-19 pneumonia. Despite numerous challenges, these findings provide valuable insights into optimizing therapeutic strategies, supporting corticosteroids as a preferred treatment over siltuximab in this setting.
Filiaciones:
Leal, L:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
González, MDB:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Castán, C:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Meira, F:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Dueñas, G:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Pich, J:
Hosp Clin Barcelona, Clin Trials Unit, Barcelona, Spain
Hernández-Meneses, M:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Rico, V:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
García-Pouton, N:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Agüero, D:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
de Lazzari, E:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Tomé, A:
Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain
Herrera, S:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Muñóz, J:
Univ Barcelona, Fac Med, Barcelona, Spain
Inst Global Hlth ISGlobal, Barcelona, Spain
Hosp Clin Barcelona, Dept Int Hlth, Barcelona, Spain
Almuedo, A:
Univ Barcelona, Fac Med, Barcelona, Spain
Inst Global Hlth ISGlobal, Barcelona, Spain
Hosp Clin Barcelona, Dept Int Hlth, Barcelona, Spain
Prieto-González, S:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain
Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain
Castro, P:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain
Marcos, MA:
Univ Barcelona, Fac Med, Barcelona, Spain
Inst Global Hlth ISGlobal, Barcelona, Spain
Hosp Clin Barcelona, Dept Microbiol, Barcelona, Spain
Tuset, M:
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Dept Pharm, Div Med, Barcelona, Spain
:
Germans Trias & Pujol Univ Hosp, Dept Infect Dis Serv, Badalona, Spain
Carbonell, C:
Univ Hosp Salamanca, Dept Internal Med, Salamanca, Spain
Dalmau, D:
Mutua Terrassa Univ Hosp, Terrassa, Spain
Martínez, JA:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
Soriano, A:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
García, F:
Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain
Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Univ Barcelona, Fac Med, Barcelona, Spain
Green Submitted, gold
|